Manifestaciones reumáticas de los pacientes con cáncer

Abstract

Cancer can be complicated by paraneoplastic rheumatic syndromes and some rheumatic conditions may increase the risk of certain cancers. On the other hand, oncological and rheumatologic treatments can lead to rheumatic manifestations and the tumor itself, causing skeletal muscle symptomatology. The rheumatic manifestations of cancer patients are described in all contexts; correlations between the specific diagnoses are sought according to their frequency and association and it is determined whether the rheumatic manifestations related to the use of oncological treatments are drug and/or dose-dependent In patients with colorectal cancer, the history of rheumatic disease is half as frequent as in other cancers, while it is more common in patients with genitourinary cancer. There was no association between the treatment given for rheumatologic diseases and the type of cancer developed later. The history of systemic rheumatologic disease was eight times more frequent in patients with breast cancer and five times less frequent in patients with genitourinary cancer. Patients with breast cancer are at eleven times greater risk than those who do not for the subsequent development of inflammatory or arthritic pain. Patients with miscellaneous-type tumors are three times more likely to develop post-inflammatory pain or arthritis than those without tumors. Hormone therapy, radiation therapy, and tyrosine kinase inhibitor drugs or the mTOR route increase the risk of inflammatory pain or arthritis. In contrast, those who received chemotherapy or monoclonal antibodies had a lower risk.